Denemek ALTIN - Özgür
"We recognise the growing demand for skilled talent in fields like Al, Gen Al, Robotics, and Data Analytics"
Bio Spectrum
|March 2025
Takeda, a global leader in biopharmaceutical innovation from Japan has opened its Innovation Capability Center (ICC) in Bengaluru.

This marks Takeda’s first ICC in Asia, following successful establishments in Slovakia and Mexico. The ICC supports the company’s dedication to advancing healthcare through innovative solutions. These cutting-edge solutions will help advance its operations and have an impact on Takeda’s workforce, the patients that it serves and the planet for years to come. In an interaction with BioSpectrum, Tilak Banerjee, Head of Takeda ICC India shared how this centre is different from other centres and the kind of partnerships it will have in place to support Takeda Group of Companies. Edited excerpts:
Takeda has opened its third Innovation Capability Center (ICC) in Bengaluru, India, following those in Slovakia (2021) and Mexico (2024). How is this centre different from the other locations?
Takeda’s ICC India stands out by leveraging the country’s unique technological strengths and innovation ecosystem to enhance the company’s global innovation efforts. The Bengaluru centre draws from the country’s rich pool of engineering talent and its culture of creative problem-solving to address complex challenges with innovative solutions. This ICC is designed to create smart, efficient solutions that can be rapidly developed and deployed across various global contexts. In addition to developing patient-centric technologies, the centre focuses on designing applications that transform the employee experience, further demonstrating its commitment to innovation. The ICC India’s emphasis on integrating local talent and expertise into Takeda’s global framework ensures it brings distinct value to the company’s digital transformation and operational excellence.
With 275 skilled professionals already on board in Bengaluru, what kind of digital solutions is the India centre offering to the Takeda Group of Companies?
Bu hikaye Bio Spectrum dergisinin March 2025 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Bio Spectrum'den DAHA FAZLA HİKAYE

Bio Spectrum
India's Pharma Reforms Target Global Credibility
The Indian government has introduced several measures to simplify drug approvals and support innovation.
9 mins
October 2025

Bio Spectrum
How Waste Management Strategies Can Transform Indian Pharma Manufacturing
Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.
7 mins
October 2025

Bio Spectrum
IASST synthesises new compound to combat aggressive breast cancer
A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.
1 min
October 2025
Bio Spectrum
DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.
1 min
October 2025

Bio Spectrum
WHO unveils updated guideline on HIV service delivery
WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.
1 min
October 2025
Bio Spectrum
Scientists in Kolkata explore therapeutic potential of accessory proteins
A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.
1 min
October 2025

Bio Spectrum
US FDA advances rare disease drug development
The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.
1 min
October 2025
Bio Spectrum
WHO updates list of essential medicines to include key cancer, diabetes treatments
The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.
1 min
October 2025
Bio Spectrum
Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification
Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.
1 min
October 2025
Bio Spectrum
Aodh Lifesciences gets support from TDB to redefine pneumonia treatment
The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).
1 min
October 2025
Listen
Translate
Change font size